SG155236A1 - Improved modalities for the treatment of degenerative diseases of the retina - Google Patents

Improved modalities for the treatment of degenerative diseases of the retina

Info

Publication number
SG155236A1
SG155236A1 SG200905546-8A SG2009055468A SG155236A1 SG 155236 A1 SG155236 A1 SG 155236A1 SG 2009055468 A SG2009055468 A SG 2009055468A SG 155236 A1 SG155236 A1 SG 155236A1
Authority
SG
Singapore
Prior art keywords
retina
treatment
degenerative diseases
improved modalities
retinal
Prior art date
Application number
SG200905546-8A
Other languages
English (en)
Inventor
Irina V Klimanskaya
Robert Lanza
Original Assignee
Advanced Cell Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cell Tech Inc filed Critical Advanced Cell Tech Inc
Publication of SG155236A1 publication Critical patent/SG155236A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
SG200905546-8A 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina SG155236A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23

Publications (1)

Publication Number Publication Date
SG155236A1 true SG155236A1 (en) 2009-09-30

Family

ID=34807248

Family Applications (4)

Application Number Title Priority Date Filing Date
SG200905546-8A SG155236A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
SG2013009170A SG188122A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
SG10201606441SA SG10201606441SA (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
SG10201912182UA SG10201912182UA (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG2013009170A SG188122A1 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
SG10201606441SA SG10201606441SA (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina
SG10201912182UA SG10201912182UA (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Country Status (15)

Country Link
US (6) US7736896B2 (fr)
EP (8) EP4248752A3 (fr)
JP (10) JP2007522131A (fr)
KR (3) KR101398356B1 (fr)
CN (3) CN104434979A (fr)
AU (6) AU2005207042B2 (fr)
BR (1) BRPI0507074A (fr)
CA (2) CA2555370C (fr)
ES (1) ES2721174T3 (fr)
HK (3) HK1216068A1 (fr)
IL (3) IL177015B (fr)
MX (2) MX343606B (fr)
NZ (1) NZ548929A (fr)
SG (4) SG155236A1 (fr)
WO (1) WO2005070011A2 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) * 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP4248752A3 (fr) 2004-01-23 2024-01-03 President And Fellows Of Harvard College Modalites ameliorees du traitement des maladies degeneratives de la retine
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
KR20150142061A (ko) 2006-05-03 2015-12-21 오카타 세라퓨틱스, 인크. 배아 줄기 세포 및 배-유도 세포의 유도
EP2128244A4 (fr) * 2007-01-18 2012-05-09 Riken Procede d'induction/differenciation dans une cellule photoreceptrice
EP3190178A1 (fr) 2007-02-23 2017-07-12 Astellas Institute for Regenerative Medicine Procedes hautement efficaces pour reprogrammer des cellules differenciees et pour produire des animaux et des cellules souches embryonnaires a partir de cellules reprogrammees
ES2530370T5 (es) * 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
WO2008137115A1 (fr) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Cellules souches multipotentes et leurs utilisations
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
WO2009051671A1 (fr) 2007-10-12 2009-04-23 Advanced Cell Technology, Inc. Procédés améliorés pour la production de cellules rpe et de compositions de cellules rpe
WO2009132156A1 (fr) * 2008-04-22 2009-10-29 Regenerative Research Foundation Cellules souches de l'épithélium pigmentaire rétinien
EP2470645B1 (fr) 2009-08-24 2019-06-26 Wisconsin Alumni Research Foundation Progéniteur rétinien humain sensiblement pur, progéniteur de cerveau antérieur, et cultures de cellules d'épithélium pigmentaire rétinien et leurs procédés de fabrication
KR102073730B1 (ko) * 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
WO2012009377A2 (fr) 2010-07-12 2012-01-19 University Of Southern California Substrat biocompatible destiné à faciliter les interconnexions entres les cellules souches et les tissus cibles et procédés d'implantation associés
WO2012012803A2 (fr) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Procédés de détection de sous-populations rares de cellules et compositions de cellules très purifiées
WO2013015835A1 (fr) 2011-07-22 2013-01-31 Seven Networks, Inc. Optimisation de trafic d'application mobile
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012158561A1 (fr) 2011-05-13 2012-11-22 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Utilisation de zscan4 et gènes dépendant de zscan4 pour reprogrammation directe de cellules somatiques
CN105349492B (zh) 2011-05-18 2019-04-16 加利福尼亚大学董事会 用于治疗视网膜疾病的组合物及方法
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
CA2855941A1 (fr) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Preparations pharmaceutiques de cellules de rpe humaines et leurs utilisations
ES2690212T3 (es) 2011-11-30 2018-11-19 Astellas Institute For Regenerative Medicine Células estromales mesenquimales y usos relacionados con las mismas
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
KR20140144680A (ko) * 2012-02-17 2014-12-19 더 셰펜스 아이 리써치 인스티튜트 인간의 망막 전구세포의 표현형 프로필
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
US11033586B2 (en) * 2012-08-24 2021-06-15 Riken Method for producing retinal pigment epithelial cell sheet
ES2970720T3 (es) * 2013-03-15 2024-05-30 Astellas Inst For Regenerative Medicine Fotorreceptores y progenitores de fotorreceptores producidos a partir de células madre pluripotentes
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP2980207B1 (fr) * 2013-03-25 2018-12-05 Foundation for Biomedical Research and Innovation at Kobe Procédé de tri cellulaire
EP2796545A1 (fr) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Procédés d'obtention de progéniteurs rétiniens, cellules de l'épithélium rétinien pigmenté et cellules rétiniennes neuronales
CA2931280A1 (fr) 2013-11-27 2015-06-04 Senju Pharmaceutical Co., Ltd. Application de laminine a une culture de cellules endotheliales de la cornee
EP3080248A1 (fr) 2013-12-11 2016-10-19 Pfizer Limited Procédé de production de cellules d'épithélium pigmentaire de la rétine
US11633477B2 (en) 2014-10-31 2023-04-25 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
WO2016067629A1 (fr) 2014-10-31 2016-05-06 京都府公立大学法人 Nouveau traitement de la rétine et des nerfs utilisant la laminine
KR20230132893A (ko) 2015-03-23 2023-09-18 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 망막 색소 상피(rpe) 세포 및 광수용체 전구 세포의 효능에 대한 개선된 검정법
TWI772270B (zh) 2015-08-18 2022-08-01 美商安斯泰來再生醫藥協會 臨床調配物
US11649432B2 (en) 2015-09-08 2023-05-16 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
CA2997952A1 (fr) 2015-09-08 2017-03-16 Kapil BHARTI Methode de differenciation reproductible de cellules de l'epithelium pigmentaire retinien de qualite clinique
CA2997763A1 (fr) 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Purification basee sur le tri cellulaire magnetique macs d'epithelium pigmentaire retinien derive de cellules souches
WO2017070333A1 (fr) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Production de cellules précurseurs hématopoïétiques à lignées multiples par programmation génétique
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
JP7007686B2 (ja) 2017-03-08 2022-01-25 大日本住友製薬株式会社 網膜色素上皮細胞の製造方法
IL269363B2 (en) * 2017-03-16 2024-02-01 Lineage Cell Therapeutics Inc Methods for measuring medical effects of treating retinal diseases
US20200277571A1 (en) * 2017-09-14 2020-09-03 Riken Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter
CR20200210A (es) 2017-11-15 2020-09-23 Friedrich Miescher Institute For Biomedical Res Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
CA3093074A1 (fr) 2018-03-12 2019-09-19 Nxcell Inc. Procede pour generer de multiples produits cellulaires a partir d'une seule source de cellules pluripotentes
WO2020218480A1 (fr) 2019-04-26 2020-10-29 国立研究開発法人理化学研究所 Composite comprenant une rétine neuronale, des cellules épithéliales de pigment rétinien et un hydrogel, et son procédé de production
CN114981417A (zh) 2019-10-30 2022-08-30 安斯泰来再生医药协会 生产视网膜色素上皮细胞的方法
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
TW202302839A (zh) 2021-03-09 2023-01-16 國立研究開發法人理化學研究所 低免疫原性視網膜色素上皮細胞之製造方法
CN118302517A (zh) 2021-11-19 2024-07-05 国立研究开发法人理化学研究所 片状视网膜组织的制造方法
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329556D1 (de) 1993-04-30 2000-11-16 Photogenesis Inc Transplantation des retinalen pigmentepithels
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
EP1044024A1 (fr) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Utilisation de cellules epitheliales retiniennes pigmentees pour la creation d'un site d'acception immunitaire
CA2321203A1 (fr) 1998-03-02 1999-09-10 Compucyte Corp. Analyse selective de cellules
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AU782846B2 (en) 1999-10-28 2005-09-01 University Of Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
JP2003533976A (ja) * 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
CA2456008A1 (fr) 2000-08-19 2002-02-28 Axordia Limited Differenciation de cellules souches
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
BR0115772A (pt) 2000-11-29 2004-01-13 Oculex Pharm Inc Processos para a redução ou para a prevenção da rejeição ao transplante ocular e de implantes intraoculares para uso para o mesmo
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
JP2004531262A (ja) 2001-05-15 2004-10-14 ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ ヒト胚性幹細胞由来インスリン産生細胞
US7425448B2 (en) 2001-07-12 2008-09-16 Geron Corporation Cardiomyocyte precursors from human embryonic stem cells
WO2003046141A2 (fr) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Procedes de production et d'utilisation de noyaux de cellules somatiques humaines reprogrammees et de cellules souches humaines autologues et isogeniques
JP2005519881A (ja) 2001-12-11 2005-07-07 ファイブローゲン、インコーポレーテッド 眼プロセスの抑制方法
US20050222061A1 (en) 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
EP1556063A2 (fr) * 2002-10-04 2005-07-27 TissueTech, Inc. Cultures sur membrane amniotique de cellules epitheliales pigmentaires de la retine et greffe
CN100593351C (zh) * 2002-10-08 2010-03-03 日本电气株式会社 阵列装置以及便携式终端
JP2006509537A (ja) * 2002-11-14 2006-03-23 エシコン・エンド−サージェリィ・インコーポレイテッド 組織細胞を検出するための方法および機器
US20050032126A1 (en) * 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP4248752A3 (fr) * 2004-01-23 2024-01-03 President And Fellows Of Harvard College Modalites ameliorees du traitement des maladies degeneratives de la retine
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
CN101155913B (zh) 2005-02-11 2011-07-06 新加坡科技研究局 增殖干细胞的方法
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
ES2530370T5 (es) * 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009051671A1 (fr) 2007-10-12 2009-04-23 Advanced Cell Technology, Inc. Procédés améliorés pour la production de cellules rpe et de compositions de cellules rpe
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) * 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) * 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
KR102073730B1 (ko) 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
WO2012012803A2 (fr) * 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Procédés de détection de sous-populations rares de cellules et compositions de cellules très purifiées
ES2722207T3 (es) 2011-04-29 2019-08-08 Univ Southern California Procedimientos para la crioconservación de células epiteliales de pigmento retiniano derivadas de citoblastos crecidas sobre un sustrato polimérico
CA2855941A1 (fr) 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Preparations pharmaceutiques de cellules de rpe humaines et leurs utilisations
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
EP2882846B1 (fr) 2012-06-05 2018-09-05 The Regents of the University of California Procédés et compositions pour la production rapide de cellules épithéliales pigmentées de la rétine à partir de cellules multipotentes

Also Published As

Publication number Publication date
MX343606B (es) 2016-11-11
CN104434979A (zh) 2015-03-25
WO2005070011A3 (fr) 2005-10-13
EP4248752A2 (fr) 2023-09-27
IL267126A (en) 2019-08-29
AU2019200513A1 (en) 2019-02-14
EP2438814A3 (fr) 2012-10-03
US20150328261A1 (en) 2015-11-19
US9649340B2 (en) 2017-05-16
EP1708575A2 (fr) 2006-10-11
EP4248752A3 (fr) 2024-01-03
IL291162A (en) 2022-05-01
AU2005207042B2 (en) 2010-09-09
CA2555370A1 (fr) 2005-08-04
JP2007522131A (ja) 2007-08-09
JP2018086274A (ja) 2018-06-07
EP2438816A3 (fr) 2012-10-03
NZ548929A (en) 2010-10-29
IL177015B (en) 2019-06-30
KR20120051754A (ko) 2012-05-22
SG188122A1 (en) 2013-03-28
AU2005207042A1 (en) 2005-08-04
EP4248751A2 (fr) 2023-09-27
CN1968608A (zh) 2007-05-23
JP2022153630A (ja) 2022-10-12
EP2438814A2 (fr) 2012-04-11
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
CA2937099A1 (fr) 2005-08-04
EP4269561A3 (fr) 2024-01-03
US9730962B2 (en) 2017-08-15
CN102204930B (zh) 2014-12-03
JP2015096556A (ja) 2015-05-21
SG10201606441SA (en) 2016-09-29
US7795025B2 (en) 2010-09-14
KR101258292B1 (ko) 2013-04-25
US20070031386A1 (en) 2007-02-08
JP2024038460A (ja) 2024-03-19
EP1708575A4 (fr) 2009-07-01
US20100299765A1 (en) 2010-11-25
WO2005070011A2 (fr) 2005-08-04
US20180064761A1 (en) 2018-03-08
EP2438815A2 (fr) 2012-04-11
EP2438816A2 (fr) 2012-04-11
JP2016195862A (ja) 2016-11-24
AU2010249263B2 (en) 2013-04-18
MX2020009456A (es) 2020-10-12
IL177015A0 (en) 2006-12-10
ES2721174T3 (es) 2019-07-29
HK1216068A1 (zh) 2016-10-14
CN1968608B (zh) 2011-06-29
JP2019217356A (ja) 2019-12-26
HK1207821A1 (en) 2016-02-12
HK1162931A1 (en) 2012-09-07
EP2438816B1 (fr) 2019-03-27
SG10201912182UA (en) 2020-02-27
KR20130025953A (ko) 2013-03-12
IL267126B (en) 2022-04-01
CN102204930A (zh) 2011-10-05
CA2555370C (fr) 2024-02-06
US7736896B2 (en) 2010-06-15
JP2012148085A (ja) 2012-08-09
US9040770B2 (en) 2015-05-26
BRPI0507074A (pt) 2007-06-19
JP2020146575A (ja) 2020-09-17
KR20070069087A (ko) 2007-07-02
AU2021200601A1 (en) 2021-03-04
AU2016259323B2 (en) 2019-01-31
US20110117062A1 (en) 2011-05-19
AU2016259323A1 (en) 2016-12-01
US20060018886A1 (en) 2006-01-26
KR101398356B1 (ko) 2014-05-23
AU2013201791B2 (en) 2016-08-18
EP2929782A1 (fr) 2015-10-14
EP4248751A3 (fr) 2023-11-01
JP2014079650A (ja) 2014-05-08
EP4269561A2 (fr) 2023-11-01
EP2438815A3 (fr) 2012-10-03

Similar Documents

Publication Publication Date Title
SG155236A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2006080952A3 (fr) Modalities ameliorees permettant de traiter les maladies degeneratives de la retine
WO2011063005A3 (fr) Procédés de génération de cellules humaines de l'épithélium pigmentaire rétinien (rpe) et préparations pharmaceutiques de celles-ci
EP2279247A4 (fr) Cellules souches de l'épithélium pigmentaire rétinien
WO2008157791A3 (fr) Procédés et compositions pour stimuler la neurogenèse et inhiber une dégénérescence neuronale à l'aide d'isothiazolopyrimidinones
WO2009134371A3 (fr) Insert lacrymal composite et procédés apparentés
WO2006044204A3 (fr) Progeniteurs neuronaux obtenus par culture de cellules souches embryonnaires humaines sans cellules nourricieres
WO2019070891A8 (fr) Thérapies géniques pour troubles lysosomaux
WO2007100692A3 (fr) Procédé de génération de progéniteurs rétiniens humains à partir de cellules souches embryonnaires
WO2007104541A3 (fr) Préparations et méthodes pour le traitement de troubles ophtalmiques
MX2009006685A (es) Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
WO2008029276A3 (fr) Compositions et procédés de traitement d'une maladie ophtalmique
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l'osteoformation et l'autorenouvellement des cellules
WO2011096728A3 (fr) Procédé de prolifération de cellules souches par le biais de l'activation de la signalisation des c-met/hgf et de la signalisation notch
WO2007035722A3 (fr) Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale
HK1157814A1 (en) Materials and methods relating to cell based therapies
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
WO2010062905A3 (fr) Compositions de cellules du ventricule latéral et utilisation pour le traitement de maladies neurodégénératives
WO2011045383A3 (fr) Composés 2,6 diaminopyridines appropriés pour le traitement de maladies associées aux protéines amyloïdes ou de type amyloïde pour le traitement ou la prévention de maladies ou d'états oculaires associés à une anomalie/changement pathologique dans le tissu du système visuel
WO2011005523A3 (fr) Molécules chimériques galectine-immunoglobuline
WO2010101301A9 (fr) Traitement prophylaxique et thérapeutique de la dégénérescence maculaire et de la rétinopathie à l'aide d'un prdx